Industry watchers already knew that Regeneron’s key new launches were hitting their marks, thanks to quarterly numbers Sanofi unveiled earlier this week. What they didn’t know was that top seller Eylea would fall short of expectations. But never fear, executives
read moreMylan may have toppled list prices on its generic Copaxone, but Teva isn’t worried. After far surpassing expectations for the multiple sclerosis blockbuster in the second quarter, the Israeli drugmaker says it’s still on track to rake in significant sales
read moreDays after AstraZeneca disclosed that it’s under Justice Department scrutiny for allegedly funding Iraqi terrorism, Johnson & Johnson and Roche also revealed similar inquiries from the agency. More: Roche, Johnson & Johnson pulled into Justice Department probe of alleged terrorist
read moreDogs, cats and other animals are now feeling the pain of Pfizer’s manufacturing problems that have contributed to a nationwide shortage of injectable opioids. The drugmaker has halted sales of the painkillers to veterinarians until sometime next year. More: Pfizer
read moreOverall revenues were at $4.7 billion, down 18% from the prior year period More: Teva raises earnings estimates despite continuing troubles Source: News
read morePharmaTimes talks to Sabina Syed, managing director, Visions4Health and co-chair of the Marketer of the Year steering group about the importance of the competition against an ever changing landscape. More: The role of the marketer is changing Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals